Leann Schneider Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 111 Chambers Hill Dr Ste 101, Chambersburg, PA 17201 Phone: 717-709-7997 Fax: 717-261-4725 |
Mrs. Carolyn Aileen Coss Klein, M.S. Speech-Language Pathologist Medicare: Accepting Medicare Assignments Practice Location: 111 Chambers Hill Dr Ste 101, Chambersburg, PA 17201 Phone: 717-709-7997 Fax: 717-261-4725 |
News Archive
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today it has initiated dosing in a Phase I human clinical study with ALN-TTR01. The study is aimed at evaluating the safety and tolerability of ALN-TTR01 in patients with transthyretin -mediated amyloidosis, and is also designed to provide preliminary data on human proof of concept based on measurements of TTR serum levels.
"Having HIV appears to be associated with a greater risk of death, even when the immune system is relatively robust and patients have not started treatment," according to a study published Friday in the Lancet, MedPage Today reports (Smith, 7/15).
The U.S. Food and Drug Administration today took one of the most significant steps in decades to prevent foodborne illness by finalizing the first two of seven major rules under the bipartisan FDA Food Safety Modernization Act (FSMA).
Radiation therapy is one of the most widely used cancer treatments, but it often damages normal tissue and can lead to debilitating conditions. A class of drugs known as mammalian target of rapamycin (mTOR) inhibitors can prevent radiation-induced tissue damage in mice by protecting normal stem cells that are crucial for tissue repair, according to a preclinical study published by Cell Press in the September issue of the journal Cell Stem Cell.
Researchers at the University of Minnesota and Minneapolis VA Medical Center have identified a biological marker in the brains of those exhibiting post-traumatic stress disorder (PTSD).
› Verified 8 days ago